Screener
Cullinan Therapeutics, Inc. CGEM Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336717
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,725 | $841 |
| Accrued expenses and other current liabilities | 36,237 | 36,120 |
| Operating lease liabilities, current | 666 | 780 |
| Total current liabilities | 40,628 | 37,741 |
| Operating lease liabilities, net of current portion | 1,405 | 1,903 |
| Total liabilities | 42,033 | 39,644 |
Item 1. Financial Statements.
FAQ
- What is Cullinan Therapeutics, Inc.'s accrued expenses?
- Cullinan Therapeutics, Inc. (CGEM) reported accrued expenses of $36.24M in Q2 2026.
- How has Cullinan Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Cullinan Therapeutics, Inc.'s accrued expenses increased by 49.7% year-over-year, from $24.2M to $36.24M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s accrued expenses has grown at a 50.7% compound annual growth rate (CAGR), from $4.64M to $36.12M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Cullinan Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude